FEATURES

DESCRIPTION

Also known as UPE35_UPEMJ, UPE35. Shows antibacterial activity against B.cereus, L.lactis, L.innocua, M.luteus, S.aureus, P.multoci, S.hominis, S.epidermidis and S.uberis (Ref.1, PubMed:33431675). Strong activity against M.luteus (MIC=2 uM) compared to S.hominis, S.epidermidis and S.aureus (PubMed:33431675). Acts by inducing permeabilization of bacterial membranes (PubMed:33431675). Forms amyloid fibrils which, in the presence of bacteria, aggregate on the bacterial membrane leading to severe membrane damage and cell death (Ref.3, PubMed:33431675). Monomer and homodimer (PubMed:26676975, PubMed:33431675). Assembles into amyloid fibrils (PubMed:26676975, Ref.3, PubMed:31385514, PubMed:33431675). Under lipid-free conditions, mostly forms fibrils with a cross-beta architecture, consisting of stacks of monomeric amphipathic beta-helices arranged in an antiparallel manner (PubMed:26676975, PubMed:31385514, PubMed:33431675). In the presence of bacteria or membrane lipids, fibrils switch to a cross-alpha conformation which may correlate with its antibacterial activity (PubMed:26676975, Ref.3, PubMed:31385514, PubMed:33431675).

Also known as UPE35_UPEMJ, UPE35. Shows antibacterial activity against B.cereus, L.lactis, L.innocua, M.luteus, S.aureus, P.multoci, S.hominis, S.epidermidis and S.uberis (Ref.1, PubMed:33431 ...

EXTERNAL LINKS

UPE35

Mutations

Mutation(s) distribution

Mutations table